Eurofins TRAC® Test for Monitoring Kidney Transplant Health
Kidney transplantation is the definitive treatment for end-stage renal disease (ESRD). Kidney graft rejection remains a major clinical challenge, with substantial impact on patient outcomes. Traditional surveillance methods, such as serum creatinine measurement, lack sensitivity and specificity for early graft injury detection. Although renal biopsy is considered the gold standard, it is invasive, costly, and associated with potential complications.
The Viracor Transplant Rejection Allograft Check (TRAC™ ) Kidney dd-cfDNA Test offers a novel, non-invasive diagnostic approach, utilizing donor-derived cell-free DNA (dd-cfDNA) quantification to monitor kidney transplant health. This assay leverages advanced Next-Generation Sequencing (NGS) technology to quantify dd-cfDNA in recipient plasma, detecting early transplant rejection events.
Donor-derived cfDNA is released into the recipient’s bloodstream during episodes of graft injury, which may result from antibody-mediated or cellular rejection. The TRAC™ test quantifies circulating dd-cfDNA, enabling early intervention and personalized management strategies to prolong graft survival. The assay determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts. cfDNA is extracted from plasma isolated from whole blood collected in Streck BCT tubes within seven days of collection and unbiased sequencing is performed. NGS and genome-wide recipient genotype data are then analyzed by a bioinformatics pipeline that calculates the percentage of dd-cfDNA present.
This test is not recommended during pregnancy, for identical twin transplants, multiple donor transplants, or when donors and recipients are siblings from consanguineous marriages, due to potential inaccurate results.
- Early detection and risk prediction of kidney transplant rejection
- Guidance for personalized immunosuppressive therapy regimens
- Evaluation of engraftment success and therapeutic interventions
Results report the percentage (%) of dd-cfDNA circulating in plasma.
- dd-cfDNA > 0.69%: Indicates increased risk of graft injury/rejection; warrants further clinical evaluation or intervention.
- dd-cfDNA ≤ 0.69%: Suggestive of stable graft function, lower risk of rejection.
Clinical correlation and complementary diagnostic tests (biopsy, imaging, serum markers) are essential for accurate patient management decisions.
0.5% – 60% dd-cfDNA Clinical Cutoff: 0.69% (for rejection risk assessment)
Whole Blood (EDTA), Streck cell-free DNA BCT tube (must be fully filled to maintain proper anticoagulant ratio).
Stability
- Ambient: 7 days.
- Transplantation. 2025 Jun 1;109(6):1026-1037. [PMID: 40020163]
- Front Genet. 2022 Oct 21;13:1031894. [PMID: 36339004]
- Clin Transplant. 2023 Aug;37(8):e14987. [PMID: 37026820]
- Kidney360. 2024 Aug 14. [PMID: 39141895]
- Kidney360. 2024 Oct 1;5(10):1410-1412. [PMID: 39480667]